Conmed (CNMD) EBITDA Margin (2010 - 2026)

Conmed (CNMD) has reported EBITDA Margin for 17 consecutive years, with 10.6% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA Margin fell 55.0% year-over-year to 10.6%; the trailing twelve-month figure through Jun 2026 stood at 8.04% (down 495.0% YoY), and the FY2025 full-year result was 7.46%, down 786.0% from the prior year.
• EBITDA Margin climbed to 10.6% in Q2 2026 per CNMD's latest filing, from 8.02% in the prior quarter.
• Across five years, EBITDA Margin topped out at 20.75% in Q3 2024 and bottomed at 0.44% in Q4 2022.
• Historically, EBITDA Margin has averaged 9.67% across 5 years, with a median of 9.54% in 2022.
• The sharpest annual moves came in 2023 and 2025: EBITDA Margin soared 1578 bps in 2023, then sank 1723 bps in 2025.
• Over 5 years, EBITDA Margin stood at 0.44% in 2022, then soared by 3616 bps to 15.35% in 2023, then fell by 1 bps to 15.18% in 2024, then slumped by 35 bps to 9.81% in 2025, then rose by 8 bps to 10.6% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 10.6%, 8.02%, and 9.81% for Q2 2026, Q1 2026, and Q4 2025 respectively.